Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 156

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 156
---
 T cell engineering which has enabled us to integrate certain desirable
characteristics of both the innate immune system and the adaptive immune system into a single therapeutic construct intended to optimize
cancer therapy. This novel cellular immunotherapy platform is designed to redirect T cells to eliminate tumors by building in engulfment
pathways that employ phagocytic programs, creating our CER-T cell therapy.

Phagocytosis is a vital
cellular process by which a phagocytic cell engulfs and internalizes a target for elimination and is a major mechanism for the removal
of pathogens and unwanted cells to maintain tissue homeostasis. The human body removes billions of cells daily through phagocytic processes.
Phagocytic removal employs specific cell clearance programs and machinery to eliminate target cells. The process is a crucial part of
the innate immune system and is distinct from the adaptive immune response which involves the generation of cytotoxic T cells to elicit
antigen-specific, cytolytic target elimination. Compared to traditional CAR-T cell approaches, which largely target the adaptive immune
system, we developed CER-T cell therapy to collaboratively mediate both cytotoxic and phagocytic mechanisms to optimize anti-tumor function.
By leveraging both immune responses, we believe CER-T cell therapy has the potential to eliminate cancer cells more effectively and with
fewer side effects than traditional CAR-T cell therapies.

The recognition of phagocytosis
as a therapeutic modality to directly clear cancer cells and initiate anti-tumor T cell immune responses has fueled interest in effectively
engaging phagocytes for use in cancer therapy. Macrophage cell engineering and macrophage-targeting approaches that enhance cytotoxic,
phagocytic and cytokine-mediated anti-tumor function are in development. Early clinical trial data from therapeutic candidates targeting
myeloid inhibitor function has demonstrated the potential to elicit clinical responses. However, the diverse pro-tumor functions of myelo-monocytic
cells may offset these efforts by supporting cancer cell survival, proliferation and the release of factors that may impede anti-tumor
immune responses. Limited in vivo proliferation and manufacturing challenges have also been hurdles in the development of macrophage-based
cellular therapy.

Experimental evidence demonstrates
the ability of CER-T cells to engulf targeted cells, employ cytolytic and non-cytolytic killing mechanisms, and exhibit pro-inflammatory
and antigen processing capabilities that augment the current capabilities of T cell immunotherapy. To that end, we believe CER-123